NASDAQ
1.11USD
+0.02 (+1.83%)
We have scored 11 news catalysts on AIxCrypto Holdings, Inc. (AIXC) over the past 12 months. The biggest single-day move next to one of them came Aug 19, 2026, when AIXC closed +17.4%: “Faraday Future Supports AIxC's Full Strategic Pivot to Physical AI and Robot-Sharing and Rental Operations; RoboShare Completes Its First Paid Commercial Order, With an Initial Fleet of More Than 80 Robots in Place”. Coverage across the window leans positive (average ticker sentiment +0.59). Most of the impact sits in sector technology and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
22.5M
P/E
—
EPS
—
Beta
0.57
52W range
0.593-6.48
Day range
1.10–1.16
Open
1.15
Prev close
1.09
Volume
301.6K
Avg volume
906.2K
Dividend
0.00
IPO
2015-06-23
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about AIxCrypto Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AIXC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
